Multiple Myeloma Research Review, Issue 64
In this issue:
ALGONQUIN: belamaf-Pd efficacious in triple-class refractory MM
Real-world effectiveness of belamaf monotherapy in RRMM
Inhibition of pinocytosis may mitigate ocular toxicity with belamaf
Indirect comparison of front-line DRd vs VRd for transplant-ineligible disease
Myeloma XII: post-salvage ASCT consolidation/maintenance prolongs PFS
Pom-PACE may be an effective bridging therapy for aggressive relapsed disease
Good Practice Paper – the management of transplant-eligible high-risk myeloma
Mass spectrometry-based determination of MRD feasible
Steroid-free venetoclax combo promising
The ultra-high-risk gene LILRB4 is a promising novel target for immunotherapy
Expert contributor
Professor Philip Campbell
Professor Philip Campbell is a general haematologist with broad training and experience in malignant and non-malignant haematology. His main clinical interests are malignant haematology and clinical research, particularly multicentre collaborative research in malignant haematology. His current appointments are Clinical Associate Professor, Deakin University Medical School, and Clinical Haematologist, Andrew Love Cancer Centre, Geelong Hospital, Barwon […]
Latest Publications and Videos
Stay up to date with our latest clinical information.
Explore Research Review Publications and Videos
Dive into our publications and videos content from over 50 areas of medicine including Cardiology, Diabetes, Oncology, Haematology and Psychiatry.
Terms and Conditions
Website terms of use
By using our website, you agree to follow these terms and conditions.
Privacy policy
We take your privacy seriously. To understand how we collect, use, and protect your information, please read our Privacy Policy, which is part of these terms.
Copyright and use of website content
The content of our website is protected by copyright, trademarks, and other legal rights. You can: view, download, or print a single copy of content for your personal or professional use.
You cannot: copy, modify, or distribute website content, or use our website content for commercial purposes or in other works without permission.
Links to third-party websites
The Research Review website may link to third-party websites for your convenience. However:
We do not endorse or approve their products, services, or actions.
We are not responsible for their content or how they operate.
There is no formal partnership between us and third parties unless we clearly state otherwise.
Disclaimer and limitation of liability
We do our best to keep the information on our website accurate, but we do not guarantee that it is always correct or up to date.
To the fullest extent allowed by law, we are not responsible for:
Any loss, damage, or costs you may suffer from using (or being unable to use) our website.
Any decisions you make based on the information provided.
Any business losses, such as lost profits, lost data, or business interruptions.
Governing law
These terms are governed by New Zealand law. If there is a dispute, it must be resolved in a New Zealand court.